Zhang et al. suggested that in the crystal structure of a polycomb repressive complex 2 from Chaetomium thermophilum (ctPRC2), a flexible linker region, but not the H3K27M cancer mutant peptide, better fits the electron density. Based on our new data, we agree with this alternative interpretation and provide the crystal structure of ctPRC2 bound to a bona fide H3K27M sequence.
Lianying Jiao and Xin Liu* Zhang et al. suggested that in the crystal structure of a polycomb repressive complex 2 from Chaetomium thermophilum (ctPRC2), a flexible linker region, but not the H3K27M cancer mutant peptide, better fits the electron density. Based on our new data, we agree with this alternative interpretation and provide the crystal structure of ctPRC2 bound to a bona fide H3K27M sequence.
A lthough displaying obvious sequence diversity, Chaetomium thermophilum polycomb repressive complex 2 (ctPRC2) is functionally and structurally similar to human PRC2 in both basal and stimulated states (1-3). In our initial crystallization efforts, the H3K27M cancer mutant peptide, which also inhibited the enzymatic activity of ctPRC2 in solution, was strictly required to generate ctPRC2 crystals of sufficient quality for structural determination (1). In addition, electron density that clearly corresponded to a short peptide was observed within the substrate-binding groove of the Ezh2 active site. We assigned the H3K27M peptide to the electron density primarily based on the arginine residue unambiguously found to occupy the lysine access channel, although we also noted that the mutated methionine residue was not fully resolved. However, according to Zhang et al., a linker region located at the N terminus of the VEFS [Vrn2-Emf2-Fis2-Su(z)12] domain of Suz12 from a neighboring asymmetric unit in the crystal lattice better fits the electron density. Our own reexamination of the electron density map prompted by Zhang et al. (4) also indicated this possibility.
To clarify this situation and, more important, to reveal the mechanism of H3K27M recognition by ctPRC2, we replaced the corresponding linker region with an H3K27M peptide sequence in the context of the same Ezh2-Suz12(VEFS) fusion protein that was used for crystallization previously (Fig. 1) . We obtained crystals of the sequence-modified ctPRC2 in complex with Sadenosylmethionine (SAM) and the H3K27me3-stimulating peptide in a similar crystal lattice under the same crystallization condition. We were not able to generate crystals of sufficient quality when SAM was replaced with S-adenosyl-Lhomocysteine (SAH). We determined the new crystal structure to 2.95-Å resolution, which showed that a methionine but not an arginine residue in the replaced H3K27M sequence from a neighboring asymmetric unit was inserted into the active site, contacting SAM directly (Fig. 1) .
Only the aliphatic portion of residue R26 side chain is ordered under the current condition. The remainder of the structure remained essentially identical to the published ctPRC2 structure in the stimulated state. H3K27M thus appears to use the same structural mechanism to inhibit ctPRC2 catalysis as previously suggested for human PRC2 (2, 5).
The new crystal structure of SAM and H3K27M-bound ctPRC2 in the stimulated state was deposited in the Protein Data Bank under PDB accession code 5KKL. We also updated the previously deposited PDB entries 5CH1 and 5CH2 to 5KJH and 5KJI, respectively. All other results and analyses of our original publication remain unaffected. We apologize for any confusion that this misinterpretation may have caused. 
